$0.74
1.53% day before yesterday
NYSE, Jul 03, 09:30 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Target price 2025 - Analyst rating & recommendation

VolitionRX Classifications & Recommendation:

Buy
82%
Hold
18%

VolitionRX Price Target

Target Price $3.06
Price $0.74
Potential
Number of Estimates 7
7 Analysts have issued a price target VolitionRX 2026 . The average VolitionRX target price is $3.06. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 9 Analysts recommend VolitionRX to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the VolitionRX stock has an average upside potential 2026 of . Most analysts recommend the VolitionRX stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 1.23 8.19
57.69% 565.61%
EBITDA Margin -2,091.06% -191.78%
52.83% 90.83%
Net Margin -2,192.68% -163.18%
51.58% 92.56%

6 Analysts have issued a sales forecast VolitionRX 2025 . The average VolitionRX sales estimate is

$8.2m
Unlock
. This is
524.96% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$17.9m 1,266.18%
Unlock
, the lowest is
$2.5m 87.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $1.2m 57.69%
2025
$8.2m 565.61%
Unlock
2026
$21.3m 160.43%
Unlock
2027
$100m 369.68%
Unlock
2028
$113m 13.18%
Unlock
2029
$166m 46.23%
Unlock
2030
$233m 40.81%
Unlock
2031
$285m 22.05%
Unlock
2032
$328m 15.04%
Unlock

3 Analysts have issued an VolitionRX EBITDA forecast 2025. The average VolitionRX EBITDA estimate is

$-15.7m
Unlock
. This is
31.35% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-16.2m 29.33%
Unlock
, the lowest is
$-15.1m 34.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-25.7m 25.62%
2025
$-15.7m 38.95%
Unlock
2026
$-9.8m 37.33%
Unlock

EBITDA Margin

2024 -2,091.06% 52.83%
2025
-191.78% 90.83%
Unlock
2026
-46.15% 75.94%
Unlock

6 VolitionRX Analysts have issued a net profit forecast 2025. The average VolitionRX net profit estimate is

$-13.4m
Unlock
. This is
44.38% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-4.2m 82.39%
Unlock
, the lowest is
$-20.7m 13.70%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-27.0m 23.64%
2025
$-13.4m 50.46%
Unlock
2026
$-3.1m 76.95%
Unlock
2027
$65.3m 2,218.83%
Unlock
2028
$98.1m 50.38%
Unlock
2029
$137m 39.79%
Unlock
2030
$184m 34.46%
Unlock
2031
$198m 7.52%
Unlock
2032
$217m 9.58%
Unlock

Net Margin

2024 -2,192.68% 51.58%
2025
-163.18% 92.56%
Unlock
2026
-14.46% 91.14%
Unlock
2027
65.16% 550.62%
Unlock
2028
86.59% 32.89%
Unlock
2029
82.77% 4.41%
Unlock
2030
79.04% 4.51%
Unlock
2031
69.63% 11.91%
Unlock
2032
66.33% 4.74%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.31 -0.13
38.00% 58.06%
P/E negative
EV/Sales 9.88

6 Analysts have issued a VolitionRX forecast for earnings per share. The average VolitionRX EPS is

$-0.13
Unlock
. This is
51.85% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.04 85.19%
Unlock
, the lowest is
$-0.21 22.22%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.31 38.00%
2025
$-0.13 58.06%
Unlock
2026
$-0.03 76.92%
Unlock
2027
$0.65 2,266.67%
Unlock
2028
$0.97 49.23%
Unlock
2029
$1.36 40.21%
Unlock
2030
$1.83 34.56%
Unlock
2031
$1.97 7.65%
Unlock
2032
$2.16 9.64%
Unlock

P/E ratio

Current -2.74 90.26%
2025
-5.58 103.60%
Unlock
2026
-24.18 333.33%
Unlock
2027
1.14 104.71%
Unlock
2028
0.76 33.33%
Unlock
2029
0.54 28.95%
Unlock
2030
0.40 25.93%
Unlock
2031
0.38 5.00%
Unlock
2032
0.34 10.53%
Unlock

Based on analysts' sales estimates for 2025, the VolitionRX stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 61.72 14.09%
2025
9.88 84.00%
Unlock
2026
3.79 61.60%
Unlock
2027
0.81 78.71%
Unlock
2028
0.71 11.65%
Unlock
2029
0.49 31.61%
Unlock
2030
0.35 28.98%
Unlock
2031
0.28 18.07%
Unlock
2032
0.25 13.07%
Unlock

P/S ratio

Current 58.20 6.05%
2025
9.31 84.00%
Unlock
2026
3.58 61.60%
Unlock
2027
0.76 78.71%
Unlock
2028
0.67 11.64%
Unlock
2029
0.46 31.62%
Unlock
2030
0.33 28.98%
Unlock
2031
0.27 18.06%
Unlock
2032
0.23 13.07%
Unlock

Current VolitionRX Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Jones Trading
Locked
Locked
Locked Jun 10 2025
D. Boral Capital
Locked
Locked
Locked Apr 30 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 11 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 08 2025
D. Boral Capital
Locked
Locked
Locked Apr 01 2025
D. Boral Capital
Locked
Locked
Locked Mar 31 2025
D. Boral Capital
Locked
Locked
Locked Mar 20 2025
Analyst Rating Date
Locked
Jones Trading:
Locked
Locked
Jun 10 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 30 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 11 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 08 2025
Locked
D. Boral Capital:
Locked
Locked
Apr 01 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 31 2025
Locked
D. Boral Capital:
Locked
Locked
Mar 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today